Sandeep Kumar Swain

@instpath.gov.in

Project Scientist-II
ICMR-National Institute of Child Health and Development Research (Previously as; ICMR-NIP)

Sandeep Kumar Swain


                     Download Compact PDF  
https://researchid.co/swainsandeep
Highly accomplished research scientist with 10+ years of multidisciplinary experience integrating computational biology, transnational pharmacology, and precision medicine to address complex disease therapeutics. Demonstrated expertise in bridging phytochemical discovery with network pharmacology, molecular target prediction, and experimental validation in metabolic diseases, hematologic malignancies, and neurodegenerative disorders. Proven track record of leading multi-disciplinary research projects combining next-generation sequencing, transcriptomic profiling, miRNA analysis, and computational drug repurposing with rigorous wet-lab validation.

Research Impact:
Authored 20+ peer-reviewed publications in high-impact international journals (Q1/Q2) with 587+ citations, h-index of 7, and i1O-index of 5.

EDUCATION

PhD (Biotechnology)

RESEARCH, TEACHING, or OTHER INTERESTS

Biotechnology, Plant Science, Cancer Research, Pharmacology (medical)
22

Scopus Publications

812

Scholar Citations

7

Scholar h-index

6

Scholar i10-index

Scopus Publications

  • A diagnostic randomized controlled trial to validate novel dried blood spot (DBS) based technology for prognosis and screening of leukemia transcripts: study protocol
    Saurabh Sharma, Sandeep Kumar Swain, Bhavika Rishi, Manpreet Kaur, Gratial Theres Joseph, Noreen Grace George, Neetu Kushwaha, Himanshu Dhanda, Rajkamal, Surbhi, Sumita Chaudhry, Debasish Sahoo, Aditi Jain, Amitabh Singh, Fouzia Siraj, Aroonima Misra
    Trials, 2026
    BACKGROUND: Leukemia is the most common subtype of cancer in Indian children and ranks among the top ten cancers in the adult population according to ICMR cancer registry 2022 (National Cancer Registry Programme, Cancer incidence and mortality in India 2022, 2022). Current leukemia diagnostics rely on sophisticated molecular tests that are not available at all healthcare centers, particularly in remote and tier-two cities. Access to specialized molecular diagnostics and prognostic tests is limited to fewer than 20 centers across India, serving a population of approximately 1.3 billion people (National Cancer Registry Programme, Cancer incidence and mortality in India 2022, 2022). This restricted accessibility results in delayed diagnosis, suboptimal risk stratification, increased economic burden, and higher mortality rates compared to high-income countries. METHODS: This is a multicenter, randomized, double-blind diagnostic interventional trial designed to validate a novel dried blood spot (DBS) based technology for leukemia transcript determination. The study will be conducted across five sites in India. Newly diagnosed acute leukemia patients (n = 300; 200 ALL and 100 AML) will be randomized into two arms: interventional arm (DBS-based testing) and comparator arm (conventional testing). The primary outcome is the sensitivity, specificity, and positive predictive value of the DBS-based method compared to conventional diagnostic methods. Secondary outcomes include overall survival, event-free survival, and relapse rates over one year of follow-up. DISCUSSION: This study addresses a critical gap in leukemia diagnostic accessibility in low- and middle-income countries. The novel DBS-based technology has the potential to withstand tropical temperature and humidity conditions for 24-48 h, making it suitable for transport from remote areas. Preliminary work has shown 100% specificity and 99% sensitivity compared to standard reference methods (PLoS One 13(1):e0191421, 2019). If validated, this technology could significantly improve leukemia outcomes through earlier diagnosis, better risk stratification, and reduced abandonment rates. TRIAL REGISTRATION: Clinical Trials Registry-India (CTRI): CTRI/2024/06/069601.
  • Multifaceted neuroprotective role of Buchanania lanzan seeds in diabetic neuropathy: In vivo and in silico studies
    Neelam Meher, Bikash Kisan, Sandeep Kumar Swain, Supriti Mohanty, Atish Kumar Sahoo
    Journal of Ethnopharmacology, 2026
  • Evaluating role of TNF-α in tyrosine kinase inhibitors-treated chronic myeloid leukemia
    Gratial Theres Joseph, Sandeep Kumar Swain, Himanshu Dhanda, Neetu Kushwaha, Priti Kumari, Mahek Pravin Khushalani, Rakesh Kumar, Baseer Noor, Sufian Zaheer, Aditi Jain, Ankur Jain, Sumita Chaudhry, Pranay Tanwar, Amitabh Singh, Bhavika Rishi, Aroonima Misra
    Frontiers in Hematology, 2026
    Purpose Chronic Myeloid Leukemia (CML) is characterized by the BCR-ABL1 fusion gene and is effectively managed with tyrosine kinase inhibitors (TKIs). However, therapeutic resistance and the persistence of leukemic stem cells pose challenges to achieving long-term remission. Tumor Necrosis Factor-alpha (TNF-α), a pro-inflammatory cytokine, is implicated in leukemogenesis and resistance, yet its clinical relevance in Indian CML cohorts remains underexplored. Objective This study investigates the pharmacodynamic and prognostic role of serum TNF-α levels in chronic-phase CML patients receiving first-line imatinib, aiming to evaluate its utility as a biomarker for treatment response. Methods We conducted a prospective observational study on 40 CML patients treated at Safdarjung Hospital, New Delhi. Blood samples were taken before treatment and 5–7 months after starting imatinib. ELISA was used to quantify TNF-α levels, and qRT-PCR was used to monitor BCR-ABL1 transcripts. We analyzed clinical and hematologic parameters using appropriate statistical methods. Results Imatinib treatment significantly reduced serum TNF-α (259.5 to 129.8 pg/mL; p < 0.0001), mirroring the observed decrease in BCR-ABL1 transcripts. Basically, if TNF-α stuck around (r = 0.87), patients responded poorly, whereas good outcomes correlated with its quicker clearance (r = 0.45). Conclusion Our data suggest that TNF-α represents a clinically relevant pharmacodynamic and prognostic biomarker for patients with chronic-phase CML receiving imatinib therapy. A decline in TNF-α levels was associated with a favorable therapeutic outcome, whereas failure of TNF-α to decline was indicative of an inferior outcome. TNF-α does not replace qRT-PCR–based monitoring of BCR-ABL1; however, it may be useful as an adjunctive prognostic marker, especially in resource-poor environments, pending appropriate prospective confirmation.
  • Analysis of TCGA (The Cancer Genome Atlas) Data for Prognosis, Risk Categorization, and Survival of AML Patients Using Bioinformatics
    Bhavika Rishi, Shamsuz Zaman, Fouzia Siraj, Sree Vishmaya, Himanshu Dhanda, Manpreet Kaur, Sandeep Swain, Baseer Noor, Sumita Chaudhry, Ankur Jain, Prashant Prabhakar, Amitabh Singh, Aroonima Misra
    Indian Journal of Medical and Paediatric Oncology, 2025
    Introduction Acute myeloid leukemia (AML) is a leading cause of mortality among Indian children and adults, driven by diverse genetic and epigenetic abnormalities. Limited access to genomic sequencing in India due to resource constraints has hindered a comprehensive understanding of prognostic factors specific to this population. Objectives This study aims to analyze publicly available genomic data using statistical and bioinformatics tools to identify key prognostic markers relevant to Indian AML patients. Materials and Methods The study utilized tumor/normal pair data from 200 adult de novo AML patients, obtained from The Cancer Genome Atlas (TCGA) and the Genotype-Tissue Expression database, analyzed using cBioPortal. Statistical and bioinformatics tools were employed to assess the impact of existing prognostic targets on disease response and to identify variables with clinical relevance and practical testing feasibility. Results Analysis of the TCGA-AML data set identified high-frequency gene mutations (≥ 10%) and well-defined cytogenetic subtypes, including t(8;21)(q22;q22), NPM1 mutations, and CEBPA mutations as key factors for future prognostic evaluation. These findings will contribute to the development of a prognostic scoring system using R programming in future. Conclusion This study offers insights into the cytogenetic and mutational landscape of AML in the Indian population, identifying critical genetic and cytogenetic markers with the potential to enhance prognostication, guide treatment strategies, and inform transplant decisions. Using R tools like limma and edgeR, differential expression analysis identified five key genes—NPM1, FLT3, IDH2, RUNX1, and STAG2—as significantly upregulated in AML. Notably, STAG2 emerges as a novel marker with potential prognostic significance, warranting validation in larger Indian cohorts. These findings may help uncover novel therapeutic targets not currently recognized in Western populations, paving the way for a more tailored and personalized approach to treatment in India. By leveraging global genomic databases, this research addresses regional gaps in knowledge. Future work should focus on validating these findings through large-scale studies in Indian cohorts to ensure their broader applicability and impact.
  • Mushroom Heteropolysaccharides and Their Biological Effects
    Umesh Chandra Dash, Satish Kanhar, Sandeep Kumar Swain
    Mushrooms in Sustainable Development an Industry and Environment Paradigm, 2025
    Mushroom heteropolysaccharides, mainly complex carbohydrates, are made of various monosaccharide units. The wide range of biological activities of these polysaccharides draws many researchers. This chapter deals with the impact of these polysaccharides with special reference to their therapeutic effects. The key findings unveil its immune-modulating activity that activates macrophages, natural killer cells, and dendritic cells, thereby boosting the body’s defense against infection and tumor. It also exhibits a considerable antitumor activity through various mechanisms such as induction of apoptosis, inhibition of angiogenesis, and inhibition of metastasis. Its antioxidant activity, as evidenced by free radical scavenging and induction of endogenous antioxidant enzymes, unveils its role in reducing oxidative stress. Anti-inflammatory activity is also observed with the reduction of pro-inflammatory cytokines and inhibition of key inflammatory processes. It also exhibits antimicrobial activity against various bacterial and viral pathogens. It exhibits an active role in modulating glucose homeostasis by controlling hypoglycemic and hypolipidemic conditions both in diabetes and cardiovascular conditions. It also functions as probiotic by regulating gut microbiota balance, thereby enhancing overall gut health. Certain polysaccharides, such as lentinan, polysaccharide K (PSK), and polysaccharide peptide (PSP) are known for the achievement of certain health benefits and nutrient supplement requirements. Further research is focused on determining the precise mechanisms involved in these activities, which can lead to their application in various health disorders.
  • Oxidative stress and inflammation in the pathogenesis of neurological disorders: Mechanisms and implications
    Umesh Chandra Dash, Nitish Kumar Bhol, Sandeep Kumar Swain, Rashmi Rekha Samal, Prabhat Kumar Nayak, Vishakha Raina, Sandeep Kumar Panda, Rout George Kerry, Asim K. Duttaroy, Atala Bihari Jena
    Acta Pharmaceutica Sinica B, 2025
    Neuroprotection is a proactive approach to safeguarding the nervous system, including the brain, spinal cord, and peripheral nerves, by preventing or limiting damage to nerve cells and other components. It primarily defends the central nervous system against injury from acute and progressive neurodegenerative disorders. Oxidative stress, an imbalance between the body's natural defense mechanisms and the generation of reactive oxygen species, is crucial in developing neurological disorders. Due to its high metabolic rate and oxygen consumption, the brain is particularly vulnerable to oxidative stress. Excessive ROS damages the essential biomolecules, leading to cellular malfunction and neurodegeneration. Several neurological disorders, including Alzheimer's, Parkinson's, Amyotrophic lateral sclerosis, multiple sclerosis, and ischemic stroke, are associated with oxidative stress. Understanding the impact of oxidative stress in these conditions is crucial for developing new treatment methods. Researchers are exploring using antioxidants and other molecules to mitigate oxidative stress, aiming to prevent or slow down the progression of brain diseases. By understanding the intricate interplay between oxidative stress and neurological disorders, scientists hope to pave the way for innovative therapeutic and preventive approaches, ultimately improving individuals' living standards.
  • Evaluating the efficacy and impact of neutropenic diet in pediatric hematology patients: a longitudinal cohort study on adherence, clinical outcomes, and socioeconomic factors
    Amitabh Singh, Neetu Kushwaha, Raja Srishwan, Shamsuz Zaman, Noreen Grace George, Raj Kamal, Sandeep Kumar Swain, Manpreet Kaur, Fouzia Siraj, Saurabh Sharma, Baseer Noor, Prashant Prabhakar, Bhavika Rishi, Aroonima Misra
    Frontiers in Nutrition, 2025
    Background and aimA neutropenic diet aims to reduce hospitalizations from febrile neutropenia and sepsis in pediatric hematology patients during chemotherapy. This study aimed to evaluate its effectiveness in improving mortality, morbidity, and overall outcomes while considering limitations, adherence rates, and its impact on hospital admissions and culture positivity.MethodA prospective 18-month observational study was conducted on pediatric hematology patients in a pediatric department at a tertiary care center. Using a baseline questionnaire at the introduction of a neutropenic diet, the study assessed the clinical history, diagnosis, clinicopathological parameters, dietary recommendations, and socio-demographic data of the patients. Patients were followed up for up to 1 year to evaluate diet adherence, outcomes, mortality, and morbidity, as indicated by hospital admissions for febrile neutropenia.ResultsAn analysis involving 100 patients was conducted to assess adherence to a neutropenic diet and its ramifications on clinical outcomes over a period of 18 months. Initial follow-up data were accessible for 83 patients, revealing an adherence rate of 66%, which subsequently declined to 57% following a 6-month interval. Patients were categorized as compliant or non-compliant, but no correlation was found between adherence and febrile admissions, sepsis, hospitalizations, or mortality. Among compliant patients, 62% showed sepsis signs, though only 19% had positive blood cultures in the whole study group. Non-adherence was linked to demographic factors such as large family size, financial constraints, and limited resources. The neutropenic diet showed minimal impact on morbidity and mortality.ConclusionOur study does not support the strict adherence to the neutropenic diet, as there is no evidence of reduced infections and the dietary adherence also imposes an undue financial burden on patients. Instead, focusing on the safe acquisition of food, food processing, and proper hand cleanliness will probably provide superior protection against infection.
  • Correction: Pediatric tumor microenvironment: developmental dynamics and therapy resistance (Frontiers in Oncology, (2025), 15, (1663975), 10.3389/fonc.2025.1663975)
    Noreen Grace George, Bhavika Rishi, Himanshu Dhanda, Gratial Theres Joseph, Sandeep Kumar Swain, Manpreet Kaur, Neetu Kushwaha, Raj Kamal, Pranay Tanwar, Sufian Zaheer, Shamsuz Zaman, Amitabh Singh, Fouzia Siraj, Aroonima Misra
    Frontiers in Oncology, 2025
    Correction on: George NG, Rishi B, Dhanda H, Joseph GT, Swain SK, Kaur M, Kushwaha N, Kamal R, Tanwar P, Zaheer S, Zaman S, Singh A, Siraj F and Misra A (2025) Pediatric tumor microenvironment: developmental dynamics and therapy resistance. Front. Oncol. 15:1663975. doi: 10.3389/fonc.2025.1663975.
  • Pediatric tumor microenvironment: developmental dynamics and therapy resistance
    Noreen Grace George, Bhavika Rishi, Himanshu Dhanda, Gratial Theres Joseph, Sandeep Kumar Swain, Manpreet Kaur, Neetu Kushwaha, Raj Kamal, Pranay Tanwar, Sufian Zaheer, Shamsuz Zaman, Amitabh Singh, Fouzia Siraj, Aroonima Misra
    Frontiers in Oncology, 2025
    The tumor microenvironment (TME) in pediatric cancers is profoundly shaped by the unique biological context of childhood development. Unlike adult tumors, pediatric malignancies arise in growing tissues, where evolving immune systems, dynamic stromal elements, and distinct hormonal and microbial influences converge to create highly specialized tumor-supportive niches. This review explores how developmental processes interact with tumor biology to drive immune evasion, therapy resistance, and disease progression. Key mechanisms such as extracellular matrix remodeling, metabolic reprogramming, and epigenetic plasticity are highlighted as critical contributors to treatment failure. Also, the recent advancements in nanomedicine, circulating markers makes it possible for interventions to be more precise and age-informed. The integration of developmental biology along with tumor ecosystem can emphasis the necessity of developing treatment plans that take into account risks and advantages associated with pediatric TME.
  • Validation of diagnostic screening test for pharmacogenomic targets for thiopurine drugs in indian pediatric acute lymphoblastic leukemia patients
    Gratial Theres Joseph, Sandeep Kumar Swain, Tejas Somwanshi, Aarishi Singh, Manpreet Kaur, Raj Kamal, Himanshu Dhanda, Prashant Kumar, Upasana Kaushik, Baseer Noor, Saurabh Sharma, Pranay Tanwar, Sufian Zaheer, Sumita Chaudhry, Prashant Prabhakar, Amitabh Singh, Bhavika Rishi, Aroonima Misra
    Frontiers in Pharmacology, 2025
    Background Thiopurines such as 6-mercaptopurine (6-MP) are central to maintenance therapy for pediatric acute lymphoblastic leukemia (ALL), yet their narrow therapeutic index frequently causes dose-limiting myelosuppression in genetically susceptible patients. Variants in NUDT15 and TPMT are major pharmacogenetic determinants of thiopurine intolerance, particularly in Asian populations. Despite CPIC recommendations for pre-emptive genotyping, routine pharmacogenetic testing is seldom implemented in India due to high costs and limited access to sequencing-based platforms. Aim To develop, standardize, and validate a rapid, low-cost tetra-primer ARMS-PCR assay for simultaneous detection of the most clinically relevant variants— NUDT15 c.415C>T and TPMT 3C (c.719A>G)—prioritized through comprehensive in silico analysis. Methods Missense SNPs in NUDT15 and TPMT were screened using SIFT, PolyPhen-2, PROVEAN, Meta-SNP, and SNPs&GO to identify high-impact variants. A multiplex ARMS-PCR assay was optimized and applied to 61 pediatric ALL samples. Genotyping results were validated by Sanger sequencing. Clinical correlations included hematologic toxicity, 6-MP dose intensity, and blast-percentage dynamics. Results In-silico prioritization consistently identified NUDT15 c.415C>T and TPMT 3C as the most deleterious and clinically actionable variants. Among 60 successfully genotyped patients, NUDT15 variants were detected in 16.7% (9 C/T and 1 T/T), while TPMT 3C heterozygosity was observed in 3.3%; no double-mutants were identified. ARMS-PCR showed 98.4% overall diagnostic accuracy relative to Sanger sequencing (sensitivity 90.9%, specificity 100%). NUDT15 -variant carriers exhibited significantly reduced 6-MP dose intensity (median 0.50 vs. 0.79; p < 0.0001). Blast-percentage analysis demonstrated marked reduction from baseline to follow-up (median 75%–15%; p = 0.0001), consistent with expected treatment response. Conclusion The validated ARMS-PCR assay provides a reliable, rapid, and cost-effective platform for simultaneous NUDT15 and TPMT 3C genotyping, demonstrating strong concordance with sequencing and clear clinical relevance. Its affordability and minimal infrastructure requirements make it suitable for integration into routine pre-treatment workflows in India, enabling genotype-guided thiopurine dosing and reducing the risk of treatment-related toxicity. This assay supports a scalable path toward equitable implementation of pharmacogenomics in resource-limited pediatric oncology settings.
  • Antioxidants of commercial interest from Homalium tomentosum attenuates hepatocellular necrosis: Insights from experimental and computational studies
    Satish Kanhar, Sandeep Kumar Swain, Umesh Chandra Dash, Neelam Meher, Atish Kumar Sahoo
    Spectrochimica Acta Part A Molecular and Biomolecular Spectroscopy, 2024
  • Optimization of bioactivities of solvent extracts of bark and heartwood of Pterocarpus marsupium and exploration of neuroprotective effect linking to the major Phytoconstituents
    Sandeep Kumar Swain, Bikash Kisan, Neelam Meher, Atish Kumar Sahoo
    Industrial Crops and Products, 2024
  • In silico molecular docking, antimicrobial and anti-inflammatory activities of bioactive fractions of Citrus sinensis (L.) Osbeck. peel against oral pathogens in dental caries
    Satyaprakash Dehury, Priyanka Priyadarsini, Ashirbad Nanda, Debasmita Dubey, Sandeep Kumar Swain, Biswajit Samantaray, Barsha Tripathy, Satish Kanhar
    Plant Science Today, 2024
  • Industrial importance seed kernel of Buchanania lanzan in contributing antioxidant, antidiabetic, and anticholinesterase activities
    Neelam Meher, Bikash Kisan, Sandeep Kumar Swain, Atish Kumar Sahoo
    Food Bioscience, 2024
  • Network pharmacology-based elucidation of bioactive compounds and experimental exploration of antidiabetic mechanisms of Hydrolea zeylanica
    Sandeep Kumar Swain, Umesh Chandra Dash, Satish Kanhar, Atish Kumar Sahoo
    Cellular Signalling, 2024
  • The ameliorative effect of Piper trioicum in attenuating cognitive deficit in scopolamine induced neurotoxicity in experimental rats
    Umesh Chandra Dash, Sandeep Kumar Swain, Atala Bihari Jena, Jagneshwar Dandapat, Atish Kumar Sahoo
    Journal of Ethnopharmacology, 2024
  • Amlodipine Ocular Delivery Restores Ferning Patterns and Reduces Intensity of Glycosylated Peak of Carrageenan-Induced Tear Fluid: An In-Silico Flexible Docking with IL-Β1
    Ashirbad Nanda, Rudra Narayan Sahoo, Mahendra Gour, Sandeep Kumar Swain, Debajyoti Das, Amit Kumar Nayak, Subrata Mallick
    Current Drug Delivery, 2024
  • Hydrolea zeylanica improves cognitive impairment in high-fat diet fed-streptozotocin-induced diabetic encephalopathy in rats via regulating oxidative stress, neuroinflammation, and neurotransmission in brain
    Sandeep Kumar Swain, Umesh Chandra Dash, Atish Kumar Sahoo
    Heliyon, 2022
  • Homalium zeylanicum attenuates streptozotocin-induced hyperglycemia and cellular stress in experimental rats via attenuation of oxidative stress imparts inflammation
    Deeptimayee Rout, Umesh Chandra Dash, Satish Kanhar, Sandeep Kumar Swain, Atish Kumar Sahoo
    Journal of Ethnopharmacology, 2022
  • The modulatory role of prime identified compounds in Geophila repens in mitigating scopolamine-induced neurotoxicity in experimental rats of Alzheimer's disease via attenuation of cholinesterase, β-secretase, MAPt levels and inhibition of oxidative stress imparts inflammation
    Umesh Chandra Dash, Sandeep Kumar Swain, Satish Kanhar, Purusottam Banjare, Partha Pratim Roy, Jagneshwar Dandapat, Atish Kumar Sahoo
    Journal of Ethnopharmacology, 2022
  • The modulatory role of prime identified compounds in the bioactive fraction of Homalium zeylanicum in high-fat diet fed-streptozotocin-induced type 2 diabetic rats
    Deeptimayee Rout, Umesh Chandra Dash, Satish Kanhar, Sandeep Kumar Swain, Atish Kumar Sahoo
    Journal of Ethnopharmacology, 2020
  • Ameliorative effects of Hydrolea zeylanica in streptozotocin-induced oxidative stress and metabolic changes in diabetic rats
    Sandeep Kumar Swain, Umesh Chandra Dash, Satish Kanhar, Atish Kumar Sahoo
    Journal of Ethnopharmacology, 2020

RECENT SCHOLAR PUBLICATIONS

  • A diagnostic randomized controlled trial to validate novel dried blood spot (DBS) based technology for prognosis and screening of leukemia transcripts: study protocol
    S Sharma, SK Swain, B Rishi, M Kaur, GT Joseph, NG George, ...
    Trials , 2026
    2026
  • Multifaceted neuroprotective role of Buchanania lanzan seeds in diabetic neuropathy: In vivo and in silico studies
    N Meher, B Kisan, SK Swain, S Mohanty, AK Sahoo
    Journal of Ethnopharmacology, 121447 , 2026
    2026
  • Evaluating role of TNF-α in tyrosine kinase inhibitors-treated chronic myeloid leukemia
    GT Joseph, SK Swain, H Dhanda, N Kushwaha, P Kumari, ...
    Frontiers in Hematology 5, 1709697 , 2026
    2026
  • Validation of diagnostic screening test for pharmacogenomic targets for thiopurine drugs in indian pediatric acute lymphoblastic leukemia patients
    GT Joseph, SK Swain, T Somwanshi, A Singh, M Kaur, R Kamal, ...
    Frontiers in Pharmacology 16, 1714797 , 2025
    2025
    Citations: 1
  • A Longitudinal Cohort Study Exploring Role of Neutropenic Diet-Feasibility, Applicability and Adherence With Clinical Outcomes in Lmic Setup
    A Misra, N Kushwaha, R Srishwan, S Swain, B Rishi, S Chaudhary, ...
    PEDIATRIC BLOOD & CANCER 72, S988-S989 , 2025
    2025
  • Correction: Pediatric tumor microenvironment: developmental dynamics and therapy resistance
    NG George, B Rishi, H Dhanda, GT Joseph, SK Swain, M Kaur, ...
    Frontiers in Oncology 15, 1745674 , 2025
    2025
  • Mushroom Heteropolysaccharides and Their Biological Effects
    UC Dash, S Kanhar, SK Swain
    Mushrooms in Sustainable Development, 126-142 , 2025
    2025
  • Pediatric tumor microenvironment: developmental dynamics and therapy resistance
    NG George, B Rishi, H Dhanda, GT Joseph, SK Swain, M Kaur, ...
    Frontiers in Oncology 15, 1663975 , 2025
    2025
    Citations: 1
  • Analysis of TCGA (The Cancer Genome Atlas) Data for Prognosis, Risk Categorization, and Survival of AML Patients Using Bioinformatics
    B Rishi, S Zaman, F Siraj, S Vishmaya, H Dhanda, M Kaur, S Swain, ...
    Indian Journal of Medical and Paediatric Oncology 46 (04), 384-396 , 2025
    2025
    Citations: 1
  • Evaluating the efficacy and impact of neutropenic diet in pediatric hematology patients: a longitudinal cohort study on adherence, clinical outcomes, and socioeconomic factors
    A Singh, N Kushwaha, R Srishwan, S Zaman, NG George, R Kamal, ...
    Frontiers in Nutrition 12, 1533734 , 2025
    2025
  • Oxidative stress and inflammation in the pathogenesis of neurological disorders: Mechanisms and implications
    UC Dash, NK Bhol, SK Swain, RR Samal, PK Nayak, V Raina, SK Panda, ...
    Acta Pharmaceutica Sinica B 15 (1), 15-34 , 2025
    2025
    Citations: 672
  • Antioxidants of commercial interest from Homalium tomentosum attenuates hepatocellular necrosis: Insights from experimental and computational studies
    S Kanhar, SK Swain, UC Dash, N Meher, AK Sahoo
    Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy 322, 124741 , 2024
    2024
  • COMBINATORY LAIP BASED DFN APPROACH FOR MINIMAL RESIDUAL DISEASEBY LESSER EXPLORED MARKERS
    A Misra, A Singh, B Rishi, H Dhanda, M Kaur, SK Swain
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY 46, 68-69 , 2024
    2024
  • Optimization of bioactivities of solvent extracts of bark and heartwood of Pterocarpus marsupium and exploration of neuroprotective effect linking to the major Phytoconstituents
    SK Swain, B Kisan, N Meher, AK Sahoo
    Industrial Crops and Products 221, 119416 , 2024
    2024
    Citations: 5
  • Amlodipine Ocular Delivery Restores Ferning Patterns and Reduces Intensity of Glycosylated Peak of Carrageenan-Induced Tear Fluid: An In-Silico Flexible …
    A Nanda, RN Sahoo, M Gour, SK Swain, D Das, AK Nayak, S Mallick
    Current Drug Delivery 21 (10), 1375-1385 , 2024
    2024
    Citations: 5
  • Industrial importance seed kernel of Buchanania lanzan in contributing antioxidant, antidiabetic, and anticholinesterase activities
    N Meher, B Kisan, SK Swain, AK Sahoo
    Food Bioscience 59, 104135 , 2024
    2024
    Citations: 6
  • Network pharmacology-based elucidation of bioactive compounds and experimental exploration of antidiabetic mechanisms of Hydrolea zeylanica
    SK Swain, UC Dash, S Kanhar, AK Sahoo
    Cellular Signalling 114, 110999 , 2024
    2024
    Citations: 9
  • The ameliorative effect of Piper trioicum in attenuating cognitive deficit in scopolamine induced neurotoxicity in experimental rats
    UC Dash, SK Swain, AB Jena, J Dandapat, AK Sahoo
    Journal of Ethnopharmacology 318, 116911 , 2024
    2024
    Citations: 10
  • In silico molecular docking, antimicrobial and anti-inflammatory activities of bioactive fractions of Citrus sinensis (L.) Osbeck. peel against oral pathogens in dental caries
    S Dehury, P Priyadarsini, A Nanda, D Dubey, SK Swain, B Samantaray, ...
    2024
    Citations: 2
  • Hydrolea zeylanica improves cognitive impairment in high-fat diet fed-streptozotocin-induced diabetic encephalopathy in rats via regulating oxidative stress, neuroinflammation …
    SK Swain, UC Dash, AK Sahoo
    Heliyon 8 (11) , 2022
    2022
    Citations: 29

MOST CITED SCHOLAR PUBLICATIONS

  • Oxidative stress and inflammation in the pathogenesis of neurological disorders: Mechanisms and implications
    UC Dash, NK Bhol, SK Swain, RR Samal, PK Nayak, V Raina, SK Panda, ...
    Acta Pharmaceutica Sinica B 15 (1), 15-34 , 2025
    2025
    Citations: 672
  • Hydrolea zeylanica improves cognitive impairment in high-fat diet fed-streptozotocin-induced diabetic encephalopathy in rats via regulating oxidative stress, neuroinflammation …
    SK Swain, UC Dash, AK Sahoo
    Heliyon 8 (11) , 2022
    2022
    Citations: 29
  • Ameliorative effects of Hydrolea zeylanica in streptozotocin-induced oxidative stress and metabolic changes in diabetic rats
    SK Swain, UC Dash, S Kanhar, AK Sahoo
    Journal of Ethnopharmacology 247, 112257 , 2020
    2020
    Citations: 22
  • The modulatory role of prime identified compounds in Geophila repens in mitigating scopolamine-induced neurotoxicity in experimental rats of Alzheimer's disease via attenuation …
    UC Dash, SK Swain, S Kanhar, P Banjare, PP Roy, J Dandapat, ...
    Journal of ethnopharmacology 282, 114637 , 2022
    2022
    Citations: 21
  • The modulatory role of prime identified compounds in the bioactive fraction of Homalium zeylanicum in high-fat diet fed-streptozotocin-induced type 2 diabetic rats
    D Rout, UC Dash, S Kanhar, SK Swain, AK Sahoo
    Journal of ethnopharmacology 260, 113099 , 2020
    2020
    Citations: 21
  • The ameliorative effect of Piper trioicum in attenuating cognitive deficit in scopolamine induced neurotoxicity in experimental rats
    UC Dash, SK Swain, AB Jena, J Dandapat, AK Sahoo
    Journal of Ethnopharmacology 318, 116911 , 2024
    2024
    Citations: 10
  • Network pharmacology-based elucidation of bioactive compounds and experimental exploration of antidiabetic mechanisms of Hydrolea zeylanica
    SK Swain, UC Dash, S Kanhar, AK Sahoo
    Cellular Signalling 114, 110999 , 2024
    2024
    Citations: 9
  • Homalium zeylanicum attenuates streptozotocin-induced hyperglycemia and cellular stress in experimental rats via attenuation of oxidative stress imparts inflammation
    D Rout, UC Dash, S Kanhar, SK Swain, AK Sahoo
    Journal of ethnopharmacology 283, 114649 , 2022
    2022
    Citations: 7
  • Industrial importance seed kernel of Buchanania lanzan in contributing antioxidant, antidiabetic, and anticholinesterase activities
    N Meher, B Kisan, SK Swain, AK Sahoo
    Food Bioscience 59, 104135 , 2024
    2024
    Citations: 6
  • Optimization of bioactivities of solvent extracts of bark and heartwood of Pterocarpus marsupium and exploration of neuroprotective effect linking to the major Phytoconstituents
    SK Swain, B Kisan, N Meher, AK Sahoo
    Industrial Crops and Products 221, 119416 , 2024
    2024
    Citations: 5
  • Amlodipine Ocular Delivery Restores Ferning Patterns and Reduces Intensity of Glycosylated Peak of Carrageenan-Induced Tear Fluid: An In-Silico Flexible …
    A Nanda, RN Sahoo, M Gour, SK Swain, D Das, AK Nayak, S Mallick
    Current Drug Delivery 21 (10), 1375-1385 , 2024
    2024
    Citations: 5
  • In silico molecular docking, antimicrobial and anti-inflammatory activities of bioactive fractions of Citrus sinensis (L.) Osbeck. peel against oral pathogens in dental caries
    S Dehury, P Priyadarsini, A Nanda, D Dubey, SK Swain, B Samantaray, ...
    2024
    Citations: 2
  • Validation of diagnostic screening test for pharmacogenomic targets for thiopurine drugs in indian pediatric acute lymphoblastic leukemia patients
    GT Joseph, SK Swain, T Somwanshi, A Singh, M Kaur, R Kamal, ...
    Frontiers in Pharmacology 16, 1714797 , 2025
    2025
    Citations: 1
  • Pediatric tumor microenvironment: developmental dynamics and therapy resistance
    NG George, B Rishi, H Dhanda, GT Joseph, SK Swain, M Kaur, ...
    Frontiers in Oncology 15, 1663975 , 2025
    2025
    Citations: 1
  • Analysis of TCGA (The Cancer Genome Atlas) Data for Prognosis, Risk Categorization, and Survival of AML Patients Using Bioinformatics
    B Rishi, S Zaman, F Siraj, S Vishmaya, H Dhanda, M Kaur, S Swain, ...
    Indian Journal of Medical and Paediatric Oncology 46 (04), 384-396 , 2025
    2025
    Citations: 1
  • A diagnostic randomized controlled trial to validate novel dried blood spot (DBS) based technology for prognosis and screening of leukemia transcripts: study protocol
    S Sharma, SK Swain, B Rishi, M Kaur, GT Joseph, NG George, ...
    Trials , 2026
    2026
  • Multifaceted neuroprotective role of Buchanania lanzan seeds in diabetic neuropathy: In vivo and in silico studies
    N Meher, B Kisan, SK Swain, S Mohanty, AK Sahoo
    Journal of Ethnopharmacology, 121447 , 2026
    2026
  • Evaluating role of TNF-α in tyrosine kinase inhibitors-treated chronic myeloid leukemia
    GT Joseph, SK Swain, H Dhanda, N Kushwaha, P Kumari, ...
    Frontiers in Hematology 5, 1709697 , 2026
    2026
  • A Longitudinal Cohort Study Exploring Role of Neutropenic Diet-Feasibility, Applicability and Adherence With Clinical Outcomes in Lmic Setup
    A Misra, N Kushwaha, R Srishwan, S Swain, B Rishi, S Chaudhary, ...
    PEDIATRIC BLOOD & CANCER 72, S988-S989 , 2025
    2025
  • Correction: Pediatric tumor microenvironment: developmental dynamics and therapy resistance
    NG George, B Rishi, H Dhanda, GT Joseph, SK Swain, M Kaur, ...
    Frontiers in Oncology 15, 1745674 , 2025
    2025